通心络胶囊治疗高血压伴糖尿病临床疗效

Clinical Effect of Tongxinluo Capsule in the Treatment of Hypertension and Diabetes Patients

目的:观察高血压伴2型糖尿病患者采用通心络胶囊综合治疗临床疗效及安全性。方法:按照随机数字表法将本院诊断为高血压伴2型糖尿病的180例患者分组为对照组和治疗组。对照组:采用非洛地平缓释片5 mg,晨起一粒口服,1次/d;格列齐特缓释片30 mg,晨起1粒口服,1次/d。治疗组:对照组治疗基础上加用通心络胶囊,3粒/次,3次/d。观察两组患者治疗前、后血压和血糖、血脂变化及临床疗效、不良反应。结果:治疗前,治疗组SBP和DBP及空腹血糖、餐后2 h血糖分别为(154.98±13.10)mm Hg、(102.10±4.79)mm Hg、(10.12±2.51)nmol/L、(15.98±2.12)nmol/L与对照组(155.12±12.76)mm Hg、(101.75±4.83)mm Hg、(10.15±2.48)nmol/L、(16.02±2.07)nmol/L比较(P>0.05);治疗后,治疗组SBP和DBP及空腹血糖、餐后2 h血糖分别为(117.62±6.94)mm Hg、(78.67±2.39)mm Hg、(6.47±1.39)nmol/L、(11.96±2.01)nmol/L与对照组(129.97±8.79)mm Hg、(95.23±3.61)mm Hg、(6.58±1.41)nmol/L、(12.13±1.96)nmol/L比较,两组患者血压比较(P<0.05);血糖比较(P>0.05)。治疗组治疗有效率与不良反应率分别为92.22%(83/90)、4.44%(4/90)与对照组87.78%(79/90)、12.22%(11/90)比较(P<0.05)。治疗后,两组患者TG与TC、LDL-C水平较治疗前比较均明显下降,而HDL-C较治疗前明显升高,但治疗组改善更明显(P<0.05)。结论:高血压伴2型糖尿病患者采用通心络胶囊综合治疗,其可有效改善患者血糖、血压、血脂等指标,提高临床疗效,且不良反应少,值得推广。

Objective：Observation on hypertensive patients with type 2 diabetes with the clinical efficacy and safety of com- bined treatment with Tongxinluo capsule. Methods：According to the random number table method, 180 patients in our hospital di- agnosed as hypertensive patients with type 2 diabetes mellitus were divided into control group and treatment group. Control group ： the Felodipine Sustained Release Tablets 5 mg, early morning capsules, 1 time/day;Gliclazide Sustained - release Tablets 30 mg, early morning capsules, 1 time/day. Treatment group：the control group was treated with Tongxinluo capsule,3 capsules each time, 3 times / day. The 2 groups before and after treatment were observed blood pressure and blood glucose, blood lipid changes and clinical curative effect and adverse reaction. Results ： Before the treatment, the treatment group SBP and DBP and fasting glucose, 2 h postprandial blood glucose （ 154.98 ± 13. 10） mmHg, respectively （ 102. 10 ± 4.79） mmHg, （ 10. 12 ± 2.51 ） nmolfL, （ 15.98 ± 2.12） nmol/L and those of control group were （ 155.12 ± 12.76） mmHg, （ 101.75 ± 4.83 ） mmHg, （ 10.15 ± 2.48） nmol/L, （ 16.02 ±2.07） nmol/L comparison （P 〈 0.05）. After treatment,the treatment group SBP and DBP and fasting glu- cose ,2 h postprandial blood glucose （ 117.62 ± 6. 94 ） mmHg, respectively （78.67 ± 2.39 ） mmHg, （6.47 ± 1.39 ） nmol/L, （ 11. 96 ± 2.01 ） nmol/L and those of the control group were （ 129.97 ± 8.79 ） mmHg, （95.23 ± 3.61 ） mmHg, （6.58 ± 1.41 ） nmol/ L, （ 12.13 ± 1.96 ） nmol/L Comparison of two groups of patients with blood pressure （ P 〈 0.05 ） ; blood glucose （ P 〈 0.05 ）. The therapeutic efficacy and adverse reaction rates were 92.22% （83/90）,4.44% （4/90） and in the control group 87.78% （79/ 90） , 12.22% （11/90） （ P 〈 0.05 ）. After treatment ,2 groups TG and TC, LDL - C levels were significantly decreased compared with those before treatment, and HDL - C compared with those before treatment were significantly increased, but that of the treat- ment group improved more obviously （ P 〈 0.05 ）. Conclusion ： Hypertensive patients with type 2 diabetes treated with Tongxinluo capsule treatment can effectively improve the blood glucose, blood pressure, blood lipids and other indicators and improve clinical curative effect, and have less adverse reaction. It is worth promoting.